Quick Takeaways: Why It Matters? Vivesto’s Paccal Vet program could expand treatment options in veterinary oncology, an area with significant unmet needs in canine and feline cancer care. Positive preliminary findings across two species support further clinical developmen...
Quick Takeaways: Why It Matters? OST-HER2’s potential conditional licensure could give OSAH a first-mover advantage in HER2-targeted canine osteosarcoma, an area with limited treatment options. A 2027 launch could establish a differentiated oncology franchise, while validating ...
Quick Takeaways: Why It Matters? CannEpil’s MUMS designation could give Endovia and Lupvindol an early-mover advantage in veterinary oncology pain management, particularly if the conditional pathway enables faster commercialization. A potential 2027 launch may expand cannabinoi...
Quick Takeaways: Why It Matters? Dechra has launched Laverdia (verdinexor tablets), the first and only FDA‑approved oral treatment for dogs with lymphoma, enabling at‑home therapy that can start on Day 1 after diagnosis. Canine lymphoma is one of the most common cancers i...
Featured Article Cover Story Regulatory Updates Launch Product Launch PetMeds Receives New Acquisition Proposal Corporate transaction PetMed Express has received an unsolicited, non-binding proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash. ...
Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Volition is positioning Nu.Q Vet Feline as a potential first scalable, affordable blood test for feline lymphoma, with performance (86% sensitivity at 97% specificity) strong enough to support real-world screening, not just “rule...
Quick Takeaways: Why It Matters? BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level. Ins...
